AstraZeneca shares: Hargreaves Lansdown investors are buying. Should I buy too?

AstraZeneca shares have fallen by more than 25% since last summer. Roland Head has been taking a fresh look. Is the pharma giant too cheap to ignore?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

With the UK under lockdown again, the coronavirus vaccination developed by AstraZeneca (LSE: AZN) and Oxford University looks even more important than it did in November. So I’m not surprised to see AstraZeneca shares were the most bought stock by investors on the Hargreaves Lansdown platform last week.

One reason for this may be sentiment — we’re all hoping that vaccines will allow life to return to normal this year. Investing on sentiment isn’t always profitable, but there’s also a more concrete reason. AstraZeneca’s share price has fallen by more than 25% from the all-time high of £10 seen last year, despite rising profits.

I want to increase my exposure to the healthcare sector, so I’ve been taking a fresh look at AstraZeneca. With the firm seemingly on track to deliver sustained growth over the next few years, should I be buying?

Reasons to buy

Buying companies whose performance is already improving often carries less risk than betting on turnarounds. AstraZeneca has been through a tough patch in recent years but the group’s investment in new drugs appears to be paying off. Profits are growing again as new drugs deliver growth. Sales of new medicines rose by 34% to $9.894m during the first nine months of last year, accounting for half of the group’s total sales.

Analysts expect this momentum to continue. The latest broker forecasts suggest AstraZeneca’s pre-tax profit could rise by about 30% in both 2021 and 2022. That’s pretty strong growth for a FTSE 100 share.

Rising profits are expected to be matched by strong cash generation. This could allow AstraZeneca to cut debt and return to dividend growth after several years of flat payouts.

AstraZeneca shares: is the price right?

I think AstraZeneca is a good business and I suspect its reputation will be improved by the way it’s handled the Covid-19 vaccine project. The company has committed not to make any profit from the vaccine and has produced a medicine that can be kept at ordinary fridge temperatures. This should make it cheaper, easier, and quicker to deploy, especially in emerging markets.

However, even the best companies can be too expensive at times. Paying too much for an investment can result in years of below-average returns. This is what I want to avoid. So, are AstraZeneca shares priced to buy?

As I mentioned earlier, the share price has pulled back by more than 25% from last summer’s record highs. At the time of writing, the shares are trading at under £74. This prices the stock at 20 times 2021 forecast earnings, with a dividend yield of 2.8%.

In my view, this is probably a fair price for the business, based on what we know today. However, as a value investor, I like to buy stocks when they’re trading below their fair value. AstraZeneca isn’t quite cheap enough to persuade me to buy today. But it’s certainly a stock I plan to keep watching.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Roland Head has no position in any of the shares mentioned. The Motley Fool UK has recommended Hargreaves Lansdown. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Here’s how a Stocks and Shares ISA and Lifetime ISA could supercharge my wealth!

Individual Savings Accounts (ISAs) can help UK share investors take their earnings to the next level. And their importance is…

Read more »

A person holding onto a fan of twenty pound notes
Investing Articles

A high-yield dividend ETF and an investment trust to consider this November!

Investors wanting to boost their passive income could benefit from investigating these high-yield funds and trusts, says Royston Wild.

Read more »

Investing Articles

2 of my favourite, cheap FTSE 100 growth shares this November!

These FTSE 100 growth shares could be great long-term picks to consider, reckons Royston Wild. At current prices he thinks…

Read more »

Investing Articles

Up 26%, can the BT share price really push higher still?

The BT share price has surged on several catalysts in 2024, but there’s evidence to suggest that the stock could…

Read more »

Man writing 'now' having crossed out 'later', 'tomorrow' and 'next week'
Investing Articles

What are the best dividend shares to buy right now?

As shares in B&M European Value Retail have fallen, the dividend yield has reached a 10-year high. Should investors be…

Read more »

Surprised Black girl holding teddy bear toy on Christmas
Investing Articles

My favourite FTSE 100 passive income stock that keeps the Christmas coffers full

The holiday season is expensive and can leave many consumers struggling to make ends meet. Here’s how I use a…

Read more »

Investing Articles

The latest growth forecasts suggest the Glencore share price will hit 555p!

Harvey Jones has been disappointed by the performance of the Glencore share price since he bought the commodity stock last…

Read more »

Dividend Shares

A closer look at the 11% dividend yield forecast for Phoenix Group shares

Phoenix Group shares have one of the highest dividend yields in the FTSE 100 index today. Could this be a…

Read more »